TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01381601

Intervention type: DRUG
Intervention: Targeted agents indicated in management of advanced/metastatic RCC (sunitinib, sorafenib, bevacizumab, and pazopanib)
Description: Metastatic RCC patients on either sunitinib or sorafenib or bevacizumab or pazopanib (identified based on claims) will be evaluated for presence or absence of common severe adverse events. These common severe adverse events will be identified from agent's product labels.
Study: NCT03811899

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 18F-DCFPyL
Description: The purpose of this study is to determine whether HG SOC are 18F-DCFPyL (=GCP-II)-avid and to compare the performance of this PET to CT and findings at time of surgery.
Study: NCT04518826

Intervention type: DEVICE
Intervention: fractional flow reserve
Description: FFR is a physiological functional parameter indicating the severity of ischemic myocardium perfused by a diseased coronary artery. It is measured by a pressure wire placed in the coronary artery and calculated by the ratio of pressures distal and proximal to the stenosis.
Study: NCT00817752

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ashwagandha
Description: Participants consume 3mL of Ashwagandha for 5 days. Blood work/immune cells (CD4 T-cells, CD8 T-cells, B-cells, NK cells, macrophages, IL-1, IL-6 and TNF-alpha) and psychological assessments (POMS and STAI Self-Evaluation) given at specified time intervals.
Study: NCT01721668

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Music Supported Rehabilitation
Description: Music Supported Rehabilitation -using musical exercises to improve hand and arm motor functioning.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Upper Extremity Therapy
Description: -GRASP (Graded Repetitive Arm Supplementary Program-developed Janice Eng, PhD, PT/OT Jocelyn Harris, PhD, OT, Andrew Dawson, MD, FRCP, Bill Miller, PhD, OT) protocol will be used to improve arm and hand function in people living with stroke.
Study: NCT04576585

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lexicon training
Description: Participants will receive training on the lexicon of appetite on up to 3 days during the training week. This will entail reading written definitions, watching an instructional video, eating exercises and completing training exams demonstrating they understand the distinctions between appetitive terms (hunger, desire to eat, fullness, and prospective consumption). The training will require about 30 minutes to complete. To ensure the success of training, participants must verbally describe the definitions of the outcome sensations to a member of the research team and complete a written quiz with at least 90 % correct responses. Failure to satisfactorily convey understanding of the concepts will result in an offer to repeat the training 2 more times or be rejected from the study.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Lexicon training
Description: Participants will receive training on the lexicon of appetite on up to 3 days during the training week. This will entail reading written definitions, watching an instructional video, eating exercises and completing training exams demonstrating they understand the distinctions between appetitive terms (hunger, desire to eat, fullness, and prospective consumption). The training will require about 30 minutes to complete. To ensure the success of training, participants must verbally describe the definitions of the outcome sensations to a member of the research team and complete a written quiz with at least 90 % correct responses. Failure to satisfactorily convey understanding of the concepts will result in an offer to repeat the training 2 more times or be rejected from the study.
Study: NCT00568399

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sodium thiosulfate
Description: sodium thiosulfate 12.5-25 gm/M2 after each thrice weekly hemodialysis treatments for 5 months.
Study: NCT02604134

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Prophylaxis
Description: A dental prophylaxis is a cleaning procedure performed to thoroughly clean the teeth. Prophylaxis is an important dental treatment for halting the progression of periodontal disease and gingivitis.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Prophylaxis
Description: A dental prophylaxis is a cleaning procedure performed to thoroughly clean the teeth. Prophylaxis is an important dental treatment for halting the progression of periodontal disease and gingivitis.

Intervention type: DRUG
Group type: OTHER
Intervention: Fluoride varnish
Description: Fluoride varnish is a highly concentrated form of fluoride which is applied to the tooth's surface, by a dentist, dental hygienist or other health care professional, as a type of topical fluoride therapy.

Intervention type: DRUG
Group type: OTHER
Intervention: Fluoride varnish
Description: Fluoride varnish is a highly concentrated form of fluoride which is applied to the tooth's surface, by a dentist, dental hygienist or other health care professional, as a type of topical fluoride therapy.

Intervention type: DRUG
Group type: OTHER
Intervention: Silver Nitrate
Description: a small amount will be applied to the tooth via a cotton applicator. Silver nitrate is a colorless, odorless, transparent solution used as an escharotic, dehydrating and sclerosing agent.
Study: NCT01012700

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hiltonol (poly ICLC)
Description: 2 mg administered subcutaneously or intranasally to healthy volunteers
Study: NCT04287673

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rehabilitation involving strongly the trunk
Description: The Rehabilitation involving strongly the trunk (RIST) leaded by a physiotherapist was based on exercises in different postures performed by the child each day that strongly involve the trunk to cope with balance.
Study: NCT02781636

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Device: StimGuard Protect System
Description: Lead implanted adjacent to tibial nerve. Wireless rechargeable system.
Study: NCT01421784

Intervention type: OTHER
Group type: OTHER
Intervention: cine MRI
Description: Rapid Cine-MRI for Monitoring Moving and Deforming Tumors
Study: NCT01964586

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: 2 mcg/kg dexmedetomidine was administered 10 minutes before the surgery by infiltration to the both side of the nasal septum.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine
Description: 10 ml 2% lidocaine was administered 10 minutes before the surgery by infiltration to the both side of the nasal septum.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adrenaline
Description: 12.5 mcg/ml 10 ml adrenaline was administered 10 minutes before the surgery by infiltration to the both side of the nasal septum.
Study: NCT03367091

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ekso GT gait training with high swing assistance
Description: Participant will walk for 20-minutes in the Ekso GT SmartAssist with the swing assistance set at high assistance

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ekso GT gait training with neutral swing assistance
Description: Participant will walk for 20-minutes in the Ekso GT SmartAssist with the swing assistance set at neutral

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ekso GT gait training with high swing resistance
Description: Participant will walk for 20-minutes in the Ekso GT SmartAssist with the swing assistance set at high resistance
Study: NCT00273715

Intervention type: PROCEDURE
Group type: NO_INTERVENTION
Intervention: Surgical wound closure techniques
Description: Subjects will be randomized to either receive sutures or staples during the surical procedure to close the incision

Intervention type: PROCEDURE
Group type: NO_INTERVENTION
Intervention: Surgical wound closure techniques (Comparator)
Description: Subjects will be randomized to either receive sutures or staples during the surical procedure to close the incision
Study: NCT00931515

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NuBac
Description: NuBac device implanted at the L4/5 level.
Study: NCT00348556

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nesiritide
Description: Nesiritide 0.005 ug/kg/min IV for 6 hours, then to 0.01 ug/kg/min for 6 hours then to 0.02ug/kg/min for 6 hours then to 0.03 ug/kg/min for the last 6 hours.
Study: NCT04514575

Intervention type: BIOLOGICAL
Intervention: Plasma transfusion
Description: Transfusion of allogeneic fresh frozen plasma or cryoprecipitate

Intervention type: BIOLOGICAL
Intervention: Plasma transfusion
Description: Transfusion of allogeneic fresh frozen plasma or cryoprecipitate
Study: NCT05655130

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Intraoperative 10 mg IV Dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Description: The oral methylprednisolone taper course will begin on the day of surgery and will taper as noted below:~Day 1: 24 mg orally (8 mg before breakfast; 4 mg after lunch; 4 mg after dinner; 8 mg at bedtime) Day 2: 20 mg orally (4 mg before breakfast; 4 mg after lunch; 4 mg after dinner; 8 mg at bedtime) Day 3: 16 mg orally (4 mg before breakfast; 4 mg after lunch; 4 mg after dinner; 4 mg at bedtime) Day 4: 12 mg orally (4 mg before breakfast; 4 mg after lunch; 4 mg at bedtime) Day 5: 8 mg orally (4 mg before breakfast; 4 mg at bedtime) Day 6: 4 mg orally (4 mg before breakfast)
Study: NCT00931515

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Prodisc-L
Description: Prodisc-L implanted at the L4/5 level.
Study: NCT04129736

Intervention type: DRUG
Group type: OTHER
Intervention: Teriflunomide 14 MG
Description: Blood and cerebrospinal fluid is obtained from teriflunomide treated patients with multiple sclerosis
Study: NCT01294319

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mifepristone
Study: NCT03555656

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Repeated intervention
Description: Repetition twice a year of a 2-h group session educating patients at foot hygiene and ulcer prevention

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Single session
Description: Single 2-h group session educating patients at foot hygiene and ulcer prevention
Study: NCT01294319

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mifepristone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mifepristone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mifepristone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mifepristone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mifepristone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mifepristone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mifepristone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Spironolactone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Spironolactone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Spironolactone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Spironolactone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Spironolactone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Spironolactone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Spironolactone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Spironolactone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combined

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combined

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combined

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combined

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combined

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combined

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combined

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combined

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Study: NCT01957410

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: During Cohorts 1 and 2, a single ketamine 0.5 mg/kg dose will be given as a continuous IV infusion over 40 minutes by use of an electronic syringe infusion pump. The predefined dose and infusion rate/duration should not be adjusted. If a patient is unable to tolerate the study medication, the infusion should be stopped. Within 1 week of completion of the open-label treatment phase, participants can receive a single dose of ketamine 0.5 mg/kg administered as an IV infusion over 40 minutes during an optional open-label treatment phase.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: During Cohort 2, a single placebo dose will be given as a continuous IV infusion over 40 minutes by use of an electronic syringe infusion pump. Within 1 week of completion of the double-blind treatment phase, participants can receive a single dose of ketamine 0.5 mg/kg administered as an IV infusion over 40 minutes during an optional open-label treatment phase.
Study: NCT01294319

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Study: NCT03563170

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ETBX-011
Description: Ad5 \[E1-, E2b-\]-CEA

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GI-4000
Description: Vaccine derived from recombinant Saccharomyces cerevisiae yeast expressing mutant RAS proteins
Study: NCT04012866

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic exercise training
Description: The aerobic exercise program using progressive resistive stationary bicycle training which will contain warm-up, resistive physical exercise, and cool-down. The training resistance will increase with improvement of participants' performance.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic exercise training
Description: The aerobic exercise program using progressive resistive stationary bicycle training which will contain warm-up, resistive physical exercise, and cool-down. The training resistance will increase with improvement of participants' performance.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Computerized cognitive training
Description: The computerized cognitive training program will be implemented with the brainHQ to target abilities of visuospatial processing, attention, memory, and executive function. The level of the training program will become more difficult with progress in participants' targeted cognitive abilities.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Computerized cognitive training
Description: The computerized cognitive training program will be implemented with the brainHQ to target abilities of visuospatial processing, attention, memory, and executive function. The level of the training program will become more difficult with progress in participants' targeted cognitive abilities.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control training
Description: The Control training will receive an intervention including combinations of non-aerobic physical activities and unstructured mental activities.
Study: NCT02319798

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: telephone consultations
Description: Those randomized to telephone consultation will be told to expect a call from the gastroenterology doctor at the time of their appointment.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: face-to-face consultations
Description: Those randomized to face-to-face follow up will attend their appointments in hospital
Study: NCT04645628

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MRI examination
Description: All subjects (healthy subjects and patients) will have an MRI examination with optimized sequences
Study: NCT04966442

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: GrandAides
Description: Enhanced post acute care for patients recently admitted for congestive heart failure
Study: NCT03493204

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Meal delivery
Description: The food will be pre-packaged for storage and patient will prepare these meals at home

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard pamphlet with Dietary Advice
Description: Explains how to maintain a low-sodium diet
Study: NCT01917799

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: 75mg tab of LDA once daily for 7 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin
Description: 75mg tab of LDA once daily for 7 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Heparin
Description: 0.4 mL/day of the Enoxaparin
Study: NCT04774029

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Basivertebral nerve block
Description: Temporary intraosseous basivertebral nerve block using lidocaine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine induced basivertebral nerve block
Description: Intraosseous lidocaine basivertebral nerve block
Study: NCT03563170

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: haNK for infusion
Description: NK-92 \[CD16.158V, ER IL-2\]
Study: NCT01098305

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Varenicline
Description: Participants will be randomized to receive varenicline or placebo for 12 weeks. The dosing regimen consistent with FDA guidelines will be used: Day 1-Day 3 (0.5mg once daily); Day 4-Day 7 (0.5mg twice daily); and Day 8-Day 84 (1.0mg twice daily).

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Counseling
Description: All participants will be provided with a structured behavioral counseling program, involving 6 counseling sessions by a trained NDDTC counselor. This will be a manual-based intervention and revised as needed for cultural relevance and sensitivity by Dr. Stigler. The intervention is designed to enhance awareness of the harmful effects of smokeless tobacco, assist the person in developing skills to quit and avoid relapse, and instruct the smokeless tobacco user on medication adherence, as recommended by experts in the field.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Counseling
Description: All participants will be provided with a structured behavioral counseling program, involving 6 counseling sessions by a trained NDDTC counselor. This will be a manual-based intervention and revised as needed for cultural relevance and sensitivity by Dr. Stigler. The intervention is designed to enhance awareness of the harmful effects of smokeless tobacco, assist the person in developing skills to quit and avoid relapse, and instruct the smokeless tobacco user on medication adherence, as recommended by experts in the field.
Study: NCT05504993

Intervention type: OTHER
Intervention: Frequency of AECOPD
Description: No intervention has been applied. 92 COPD patients divided into 2 groups according to their comorbidity level. Than these groups were compared for their AECOPD frequency

Intervention type: OTHER
Intervention: Frequency of AECOPD
Description: No intervention has been applied. 92 COPD patients divided into 2 groups according to their comorbidity level. Than these groups were compared for their AECOPD frequency
Study: NCT03447847

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Water
Description: 1 liter of water in meals; 1 liter out of meals

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Water
Description: 1 liter of water in meals; 1 liter out of meals

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Water
Description: 1 liter of water in meals; 1 liter out of meals

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Water
Description: 1 liter of water in meals; 1 liter out of meals
Study: NCT01589393

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enoxaparin
Description: Enoxaparin 30 mg subcutaneously twice daily for six doses starting 36-48 hours post traumatic injury.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.9% normal saline in equal volume to active comparator given subcutaneously twice daily starting 36-48 hours post traumatic injury for six doses.
Study: NCT00125736

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E0671
Description: One 50 mg capsule is orally administered three times daily (150 mg/day)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rabeprazole sodium
Description: One 10mg tablet is administered orally each day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: rabeprazole sodium
Description: One 10mg tablet is administered orally each day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: E0671 placebo
Description: One 50 mg capsule is orally administered three times daily (150 mg/day)
Study: NCT02457130

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Study: NCT00224757

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transoesophageal echocardiography
Description: TEE

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transoesophageal echocardiography
Description: TEE
Study: NCT04427306

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: T-Vec
Description: (talimogene laherparepvec) will be given prior to surgery. Standard care the patients receive the drug after sugery
Study: NCT03956459

Intervention type: OTHER
Group type: OTHER
Intervention: Patients with a cancer for which a FDG-PET scanner must be performed
Description: For each patient, 2 consecutive PET-CT scanners will be performed using 2 different systems of PET-CT scanners:~* Discovery MI~* Discovery IQ~Only one contrast agent injection (FDG) will be given for both scanners.
Study: NCT03944096

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: FMT+MTX
Description: FMT is performed at the beginning of the study and is repeated after 4 weeks plus MTX in the same dose.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: FMT+MTX
Description: FMT is performed at the beginning of the study and is repeated after 4 weeks plus MTX in the same dose.